Pathological Changes of Tau Related to Alzheimer's Disease

ACS Chem Neurosci. 2019 Feb 20;10(2):931-944. doi: 10.1021/acschemneuro.8b00457. Epub 2018 Oct 23.

Abstract

Alzheimer's disease (AD), the most common form of dementia, is characterized by extracellular β-amyloid plaques and intracellular neurofibrillary tangles (NFTs), which are considered as major targets for AD therapies. However, no effective therapy is available to cure or prevent the progression of AD up until now. Accumulation of NFTs, which consist of abnormally hyperphosphorylated tau, is directly correlated with the degree of dementia in AD patients. Emerging evidence indicates that the prion-like seeding and spreading of tau pathology may be the key driver of AD. In the past decades, greater understanding of tau pathway reveals new targets for the development of specific therapies. Here, we review the recent research progress in the mechanism underlying tau pathology in AD and briefly introduce tau-based therapeutics.

Keywords: Alzheimer’s disease; aggregation; hyperphosphorylation; propagation; tau pathology; truncation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology*
  • Animals
  • Humans
  • Neurofibrillary Tangles / metabolism
  • Neurofibrillary Tangles / pathology
  • Phosphorylation / physiology
  • Plaque, Amyloid / metabolism
  • Plaque, Amyloid / pathology
  • Protein Aggregation, Pathological / metabolism*
  • Protein Aggregation, Pathological / pathology*
  • tau Proteins / metabolism*

Substances

  • tau Proteins